US Reforms OTC Drug Monograph Process under CARES Act

On March 27, 2020, the Coronavirus Aid,
Relief, and Economic Security Act (CARES Act) was signed into law, providing economic
relief for many families and small businesses. Within the Act were measures to
reform and modernize the Over the Counter (OTC) Drug Monograph process.

In place since 1972, the traditional
monograph process had multiple steps, including the requirement that the US
Food and Drug Administration (FDA) issue:

  1. Advance Notice of Proposed Rulemaking (ANPR)
  2. Tentative Final Monograph (TFM)
  3. Final Monograph

Each step was followed by a period of public

Under the reform included in the CARES Act,
the FDA can issue administrative orders in response to OTC Monograph Order
Requests (OMORs). These requests can be initiated by either the FDA or
industry. In addition, the Act’s changes mean new annual user fees will be
assessed for any OTC monograph drug facility.

Products that are currently on the market and
marketed under ANPR and TFM are updated accordingly:

  • ANPR:
    1. Category I – treated as Category III TFM ingredient and may remain on the market pending a further FDA decision
    2. Category II – must be removed from the market within 180 days of March 27, 2020
    3. Category III – may remain on the market pending a further FDA decision
  • TFM:
    1. Category I – Final Rule
    2. Category II – same as ANPR Category II
    3. Category III – same as ANPR Category III

In addition to the changes being brought
in around the OTC Drug Monograph process, the CARES Act also sunsets the Sunscreen
Innovation Act and permits the marketing of sunscreen drug products under the
1999 Final Monograph outlined in 21 CFR 352.

In effect this, among other provisions,
reverses the proposed changes to labeling and broad-spectrum testing
requirements that were part of the proposed rulemaking. In relation to
sunscreen products, the FDA is now required to issue a new order by September
2021, with an effective date at least one year later.

SGS Cosmetics &
Personal Care Testing Services

SGS provides testing, inspection, auditing and
consulting services to manufacturers, distributors and importers to ensure a
high level of product quality in every area. A global network of
state-of-the-art laboratories offer custom-made solutions for chemical,
biophysical, microbiological, stability and biological aspects. Learn more
about SGS’s
& Personal Care Testing

In addition, SGS Digicomply is an advanced regulatory compliance
management platform that helps manufacturers stay up to date with regulatory
and legislative changes.

SGS SafeGuardS keep you up to date with
the latest news and developments in the consumer goods industry. Read the full
CARES Act Introduces OTC Monograph Reform

Subscribe here to receive SGS SafeGuardS direct to your inbox.

For further information contact:

Joseph Scognamiglio

Technical Manager

Tel: 1-973-461-7937



LinkedIn: sgs-consumer-goods-&-retail

About SGS

SGS is the world’s leading inspection, verification, testing and
certification company. SGS is recognized as the global benchmark for quality
and integrity. With more than 94,000 employees, SGS operates a network of over
2,600 offices and laboratories around the world.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top